374 related articles for article (PubMed ID: 28373365)
1. Current and Emerging Therapies in Metastatic Pancreatic Cancer.
Manji GA; Olive KP; Saenger YM; Oberstein P
Clin Cancer Res; 2017 Apr; 23(7):1670-1678. PubMed ID: 28373365
[TBL] [Abstract][Full Text] [Related]
2. Strategies for Increasing Pancreatic Tumor Immunogenicity.
Johnson BA; Yarchoan M; Lee V; Laheru DA; Jaffee EM
Clin Cancer Res; 2017 Apr; 23(7):1656-1669. PubMed ID: 28373364
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic Cancer: "A Riddle Wrapped in a Mystery inside an Enigma".
Borazanci E; Dang CV; Robey RW; Bates SE; Chabot JA; Von Hoff DD
Clin Cancer Res; 2017 Apr; 23(7):1629-1637. PubMed ID: 28373361
[TBL] [Abstract][Full Text] [Related]
4. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
[TBL] [Abstract][Full Text] [Related]
5. Re-engineering the Pancreas Tumor Microenvironment: A "Regenerative Program" Hacked.
Evan GI; Hah N; Littlewood TD; Sodir NM; Campos T; Downes M; Evans RM
Clin Cancer Res; 2017 Apr; 23(7):1647-1655. PubMed ID: 28373363
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.
Ruess DA; Görgülü K; Wörmann SM; Algül H
Drugs Aging; 2017 May; 34(5):331-357. PubMed ID: 28349415
[TBL] [Abstract][Full Text] [Related]
7. Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma.
Zhen DB; Coveler A; Zanon S; Reni M; Chiorean EG
Semin Oncol; 2018 Jun; 45(3):107-115. PubMed ID: 30391013
[TBL] [Abstract][Full Text] [Related]
8. Emerging antibodies for the treatment of pancreatic cancer.
Andrikou K; Peterle C; Pipitone S; Salati M; Cascinu S
Expert Opin Emerg Drugs; 2017 Mar; 22(1):39-51. PubMed ID: 28253833
[TBL] [Abstract][Full Text] [Related]
9. New therapeutic targets in pancreatic cancer.
Lai E; Puzzoni M; Ziranu P; Pretta A; Impera V; Mariani S; Liscia N; Soro P; Musio F; Persano M; Donisi C; Tolu S; Balconi F; Pireddu A; Demurtas L; Pusceddu V; Camera S; Sclafani F; Scartozzi M
Cancer Treat Rev; 2019 Dec; 81():101926. PubMed ID: 31739115
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
11. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
Sclafani F; Iyer R; Cunningham D; Starling N
Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
[TBL] [Abstract][Full Text] [Related]
12. Pancreas cancer: Therapeutic trials in metastatic disease.
Smithy JW; O'Reilly EM
J Surg Oncol; 2021 May; 123(6):1475-1488. PubMed ID: 33831245
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma.
Zemanek T; Melichar B; Lovecek M; Soucek P; Mohelnikova-Duchonova B
Pharmacogenomics; 2019 Jan; 20(2):113-127. PubMed ID: 30539680
[TBL] [Abstract][Full Text] [Related]
14. Novel Therapeutics for Pancreatic Adenocarcinoma.
Lowery MA; O'Reilly EM
Hematol Oncol Clin North Am; 2015 Aug; 29(4):777-87. PubMed ID: 26226910
[TBL] [Abstract][Full Text] [Related]
15. Novel systemic treatment approaches for metastatic pancreatic cancer.
Dorman K; Heinemann V; Kobold S; von Bergwelt-Baildon M; Boeck S
Expert Opin Investig Drugs; 2022 Mar; 31(3):249-262. PubMed ID: 35114868
[TBL] [Abstract][Full Text] [Related]
16. Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma.
Al Haddad AH; Adrian TE
Expert Opin Investig Drugs; 2014 Nov; 23(11):1499-515. PubMed ID: 25078674
[TBL] [Abstract][Full Text] [Related]
17. Promising new therapies in advanced pancreatic adenocarcinomas.
Kundranda M; Kachaamy T
Future Oncol; 2014 Dec; 10(16):2629-41. PubMed ID: 25531049
[TBL] [Abstract][Full Text] [Related]
18. Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges.
Diab M; Azmi A; Mohammad R; Philip PA
Expert Opin Pharmacother; 2019 Apr; 20(5):535-546. PubMed ID: 30592647
[TBL] [Abstract][Full Text] [Related]
19. The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities.
Tesfaye AA; Kamgar M; Azmi A; Philip PA
Expert Rev Anticancer Ther; 2018 Feb; 18(2):131-148. PubMed ID: 29254387
[TBL] [Abstract][Full Text] [Related]
20. Targeting the Tumor Stroma: the Biology and Clinical Development of Pegylated Recombinant Human Hyaluronidase (PEGPH20).
Wong KM; Horton KJ; Coveler AL; Hingorani SR; Harris WP
Curr Oncol Rep; 2017 Jul; 19(7):47. PubMed ID: 28589527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
